{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T05:20:29Z","timestamp":1738905629451,"version":"3.37.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,6]]},"DOI":"10.7759\/cureus.78618","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T12:43:16Z","timestamp":1738845796000},"source":"Crossref","is-referenced-by-count":0,"title":["Isocitrate Dehydrogenase 2 (IDH2)-Mutant Metastatic Esthesioneuroblastoma: A Case Report and Review of Current Therapeutic Options"],"prefix":"10.7759","author":[{"given":"Rita","family":"Banha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rute","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charalampos S","family":"Floudas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2019.03.014","article-title":"Esthesioneuroblastoma: a comprehensive review of diagnosis, management, and current treatment options","volume":"126","author":"Fiani B","year":"2019","unstructured":"Fiani B, Quadri SA, Cathel A, et al.. Esthesioneuroblastoma: a comprehensive review of diagnosis, management, and current treatment options. World Neurosurg. 2019, 126:194-211. 10.1016\/j.wneu.2019.03.014","journal-title":"World Neurosurg"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1242453","article-title":"Olfactory neuroblastoma: diagnosis, management, and current treatment options","volume":"13","author":"Tosoni A","year":"2023","unstructured":"Tosoni A, Di Nunno V, Gatto L, Corradi G, Bartolini S, Ranieri L, Franceschi E. Olfactory neuroblastoma: diagnosis, management, and current treatment options. Front Oncol. 2023, 13:1242453. 10.3389\/fonc.2023.1242453","journal-title":"Front Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000521736","article-title":"Management of esthesioneuroblastoma: a retrospective study of 6 cases and literature review","volume":"15","author":"Alami Z","year":"2022","unstructured":"Alami Z, Farhane FZ, Bouziane A, Mhirech S, Amrani Joutei S, Hassani W, Bouhafa T. Management of esthesioneuroblastoma: a retrospective study of 6 cases and literature review. Case Rep Oncol. 2022, 15:176-86. 10.1159\/000521736","journal-title":"Case Rep Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051506","article-title":"Recurrent esthesioneuroblastoma: long-term outcomes of salvage therapy","volume":"15","author":"Ni G","year":"2023","unstructured":"Ni G, Pinheiro-Neto CD, Iyoha E, et al.. Recurrent esthesioneuroblastoma: long-term outcomes of salvage therapy. Cancers (Basel). 2023, 15:1506. 10.3390\/cancers15051506","journal-title":"Cancers (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22373","article-title":"Hyams grading as a predictor of metastasis and overall survival in esthesioneuroblastoma: a meta-analysis","volume":"9","author":"Goshtasbi K","year":"2019","unstructured":"Goshtasbi K, Abiri A, Abouzari M, et al.. Hyams grading as a predictor of metastasis and overall survival in esthesioneuroblastoma: a meta-analysis. Int Forum Allergy Rhinol. 2019, 9:1054-62. 10.1002\/alr.22373","journal-title":"Int Forum Allergy Rhinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2020.08.227","article-title":"Extraprimary local recurrence of esthesioneuroblastoma: case series and literature review","volume":"144","author":"Maina IW","year":"2020","unstructured":"Maina IW, Lehrich BM, Goshtasbi K, et al.. Extraprimary local recurrence of esthesioneuroblastoma: case series and literature review. World Neurosurg. 2020, 144:e546-52. 10.1016\/j.wneu.2020.08.227","journal-title":"World Neurosurg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/lary.25862","article-title":"Patterns of regional and distant metastasis in esthesioneuroblastoma","volume":"126","author":"Banuchi VE","year":"2016","unstructured":"Banuchi VE, Dooley L, Lee NY, et al.. Patterns of regional and distant metastasis in esthesioneuroblastoma. Laryngoscope. 2016, 126:1556-61. 10.1002\/lary.25862","journal-title":"Laryngoscope"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/hed.25209","article-title":"Esthesioneuroblastoma with distant metastases: systematic review & meta-analysis","volume":"40","author":"Marinelli JP","year":"2018","unstructured":"Marinelli JP, Janus JR, Van Gompel JJ, et al.. Esthesioneuroblastoma with distant metastases: systematic review &amp; meta-analysis. Head Neck. 2018, 40:2295-303. 10.1002\/hed.25209","journal-title":"Head Neck"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0287","article-title":"Comprehensive genomic profiling of esthesioneuroblastoma reveals additional treatment options","volume":"22","author":"Gay LM","year":"2017","unstructured":"Gay LM, Kim S, Fedorchak K, et al.. Comprehensive genomic profiling of esthesioneuroblastoma reveals additional treatment options. Oncologist. 2017, 22:834-42. 10.1634\/theoncologist.2016-0287","journal-title":"Oncologist"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-199805000-00040","article-title":"Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience","volume":"42","author":"McElroy EA Jr","year":"1998","unstructured":"McElroy EA Jr, Buckner JC, Lewis JE. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery. 1998, 42:1023-7; discussion 1027-8. 10.1097\/00006123-199805000-00040","journal-title":"Neurosurgery"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0347(200009)22:6<550::aid-hed2>3.0.co;2-0","article-title":"Esthesioneuroblastoma: the Johns Hopkins experience","volume":"22","author":"Resto VA","year":"2000","unstructured":"Resto VA, Eisele DW, Forastiere A, Zahurak M, Lee DJ, Westra WH. Esthesioneuroblastoma: the Johns Hopkins experience. Head Neck. 2000, 22:6-550. 10.1002\/1097-0347(200009)22:6&lt;550::aid-hed2&gt;3.0.co;2-0","journal-title":"Head Neck"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23246","article-title":"Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: a retrospective analysis of 12 cases","volume":"112","author":"Kiyota N","year":"2008","unstructured":"Kiyota N, Tahara M, Fujii S, et al.. Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: a retrospective analysis of 12 cases. Cancer. 2008, 112:885-91. 10.1002\/cncr.23246","journal-title":"Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1023\/b:neon.0000040826.30636.4a","article-title":"Intracranial metastatic esthesioneuroblastoma responsive to temozolomide","volume":"70","author":"Wick W","year":"2004","unstructured":"Wick W, Wick A, K\u00fcker W, Dichgans J, Weller M. Intracranial metastatic esthesioneuroblastoma responsive to temozolomide. J Neurooncol. 2004, 70:73-5. 10.1023\/b:neon.0000040826.30636.4a","journal-title":"J Neurooncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00486","article-title":"Durable major response with pazopanib in recurrent, heavily pretreated metastatic esthesioneuroblastoma harboring a fumarate hydratase mutation","volume":"5","author":"Spengler M","year":"2021","unstructured":"Spengler M, Wheelden M, Mackley HB, Drabick JJ. Durable major response with pazopanib in recurrent, heavily pretreated metastatic esthesioneuroblastoma harboring a fumarate hydratase mutation. JCO Precis Oncol. 2021, 5:10.1200\/PO.20.00486","journal-title":"JCO Precis Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-009-0027-x","article-title":"Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate","volume":"97","author":"Preusser M","year":"2010","unstructured":"Preusser M, Hutterer M, Sohm M, et al.. Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate. J Neurooncol. 2010, 97:305-8. 10.1007\/s11060-009-0027-x","journal-title":"J Neurooncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2021.11.103","article-title":"Clinicopathologic features and prognosis of olfactory neuroblastoma with isocitrate dehydrogenase 2 mutations","volume":"159","author":"Wu L","year":"2022","unstructured":"Wu L, An J, Liu H. Clinicopathologic features and prognosis of olfactory neuroblastoma with isocitrate dehydrogenase 2 mutations. World Neurosurg. 2022, 159:e23-31. 10.1016\/j.wneu.2021.11.103","journal-title":"World Neurosurg"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.09.047","article-title":"Integrated multi-omic analysis of esthesioneuroblastomas identifies two subgroups linked to cell ontogeny","volume":"25","author":"Classe M","year":"2018","unstructured":"Classe M, Yao H, Mouawad R, et al.. Integrated multi-omic analysis of esthesioneuroblastomas identifies two subgroups linked to cell ontogeny. Cell Rep. 2018, 25:811-21.e5. 10.1016\/j.celrep.2018.09.047","journal-title":"Cell Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3183","article-title":"Phase II study of enasidenib in IDH2-mutated malignant sinonasal and skull base tumors","volume":"42","author":"Xue E","year":"2024","unstructured":"Xue E, Bracken-Clarke DM, Reed M, et al.. Phase II study of enasidenib in IDH2-mutated malignant sinonasal and skull base tumors. J Clin Oncol. 2024, 42:10.1200\/JCO.2024.42.16_suppl.TPS3183","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.237990","article-title":"Efficacy of peptide receptor radionuclide therapy for esthesioneuroblastoma","volume":"61","author":"Hasan OK","year":"2020","unstructured":"Hasan OK, Ravi Kumar AS, Kong G, Oleinikov K, Ben-Haim S, Grozinsky-Glasberg S, Hicks RJ. Efficacy of peptide receptor radionuclide therapy for esthesioneuroblastoma. J Nucl Med. 2020, 61:1326-30. 10.2967\/jnumed.119.237990","journal-title":"J Nucl Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/323873-isocitrate-dehydrogenase-2-idh2-mutant-metastatic-esthesioneuroblastoma-a-case-report-and-review-of-current-therapeutic-options","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T12:43:18Z","timestamp":1738845798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/323873-isocitrate-dehydrogenase-2-idh2-mutant-metastatic-esthesioneuroblastoma-a-case-report-and-review-of-current-therapeutic-options"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.78618","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}